BACKGROUND: Vaccinia virus, one of the best known members of poxvirus family, has a wide host range both in vivo and in vitro. The expression of Flt3 ligand (FL) by recombinant vaccinia virus (rVACV) highly influenced properties of the virus in dependence on the level of expression. RESULTS: High production of FL driven by the strong synthetic promoter decreased the growth of rVACV in macrophage cell line J774.G8 in vitro as well as its multiplication in vivo when inoculated in mice. The inhibition of replication in vivo was mirrored in low levels of antibodies against vaccinia virus (anti-VACV) which nearly approached to the negative serum level in non-infected mice. Strong FL expression changed not only the host range of the recombinant but also the basic protein contents of virions. The major proteins - H3L and D8L - which are responsible for the virus binding to the cells, and 28 K protein that serves as a virulence factor, were changed in the membrane portion of P13-E/L-FL viral particles. The core virion fraction contained multiple larger, uncleaved proteins and a higher amount of cellular proteins compared to the control virus. The overexpression of FL also resulted in its incorporation into the viral core of P13-E/L-FL IMV particles. In contrary to the equimolar ratio of glycosylated and nonglycosylated FL forms found in cells transfected with the expression plasmid, the recombinant virus incorporated mainly the smaller, nonglycosylated FL. CONCLUSIONS: It has been shown that the overexpression of the Flt3L gene in VACV results in the attenuation of the virus in vivo.

Institute of Hematology and Blood Transfusion Department of Experimental Virology U Nemocnice 1 CZ 128 20 Prague 2 Czech Republic

Zobrazit více v PubMed

Mackett M, Smith GL. Vaccinia Virus Expression Vectors. J Gen Virol. 1986;67:2067–2082. doi: 10.1099/0022-1317-67-10-2067. PubMed DOI

Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A Receptor Tyrosine Kinase Specific to Hematopoietic Stem and Progenitor Cell-Enriched Populations. Cell. 1991;65:1143–1152. doi: 10.1016/0092-8674(91)90010-V. PubMed DOI

McKenna HJ, de Vries P, Brasel K, Lyman SD, Williams DE. Effect of Flt3 Ligand on the Ex Vivo Expansion of Human CD34+ Hematopoietic Progenitor Cells. Blood. 1995;86:3413–3420. PubMed

Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR. Molecular Cloning of a Ligand for the Flt3/Flk-2 Tyrosine Kinase Receptor: a Proliferative Factor for Primitive Hematopoietic Cells. Cell. 1993;75:1157–1167. doi: 10.1016/0092-8674(93)90325-K. PubMed DOI

Hudak S, Hunte B, Culpepper J, Menon S, Hannum C, Thompson-Snipes L, Rennick D. FLT3/FLK2 Ligand Promotes the Growth of Murine Stem Cells and the Expansion of Colony-Forming Cells and Spleen Colony-Forming Units. Blood. 1995;85:2747–2755. PubMed

Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, Hooley J, Bauer K, Matthews W. Cellular and Molecular Characterization of the Role of the Flk-2/Flt-3 Receptor Tyrosine Kinase in Hematopoietic Stem Cells. Blood. 1994;84:2422–2430. PubMed

Rusten LS, Lyman SD, Veiby OP, Jacobsen SE. The FLT3 Ligand Is a Direct and Potent Stimulator of the Growth of Primitive and Committed Human CD34+ Bone Marrow Progenitor Cells in Vitro. Blood. 1996;87:1317–1325. PubMed

Shah AJ, Smogorzewska EM, Hannum C, Crooks GM. Flt3 Ligand Induces Proliferation of Quiescent Human Bone Marrow CD34+ Blood. 1996;87:3563–3570. PubMed

Solanilla A, Grosset C, Duchez P, Legembre P, Pitard V, Dupouy M, Belloc F, Viallard JF, Reiffers J, Boiron JM, Coulombel L, Ripoche J. Flt3-Ligand Induces Adhesion of Haematopoietic Progenitor Cells Via a Very Late Antigen (VLA)-4- and VLA-5-Dependent Mechanism. Br J Haematol. 2003;120:782–786. doi: 10.1046/j.1365-2141.2003.04155.x. PubMed DOI

Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD. Hematologic Effects of Flt3 Ligand in Vivo in Mice. Blood. 1996;88:2004–2012. PubMed

Antonysamy MA, Thomson AW. Flt3 Ligand (FL) and Its Influence on Immune Reactivity. Cytokine. 2000;12:87–100. doi: 10.1006/cyto.1999.0540. PubMed DOI

McKenna HJ, Stocking KL, Miller RE, Brasel K, De ST, Maraskovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B, Roux ER, Teepe M, Lyman SD, Peschon JJ. Mice Lacking Flt3 Ligand Have Deficient Hematopoiesis Affecting Hematopoietic Progenitor Cells, Dendritic Cells, and Natural Killer Cells. Blood. 2000;95:3489–3497. PubMed

Dravid G, Rao SG. Ex Vivo Expansion of Stem Cells From Umbilical Cord Blood: Expression of Cell Adhesion Molecules. Stem Cells. 2002;20:183–189. doi: 10.1634/stemcells.20-2-183. PubMed DOI

Muench MO, Humeau L, Paek B, Ohkubo T, Lanier LL, Albanese CT, Barcena A. Differential Effects of Interleukin-3, Interleukin-7, Interleukin 15, and Granulocyte-Macrophage Colony-Stimulating Factor in the Generation of Natural Killer and B Cells From Primitive Human Fetal Liver Progenitors. Exp Hematol. 2000;28:961–973. doi: 10.1016/S0301-472X(00)00490-2. PubMed DOI

Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J. Ligand for FLT3/FLK2 Receptor Tyrosine Kinase Regulates Growth of Haematopoietic Stem Cells and Is Encoded by Variant RNAs. Nature. 1994;368:643–648. doi: 10.1038/368643a0. PubMed DOI

Lyman SD, James L, Zappone J, Sleath PR, Beckmann MP, Bird T. Characterization of the Protein Encoded by the Flt3 (Flk2) Receptor-Like Tyrosine Kinase Gene. Oncogene. 1993;8:815–822. PubMed

Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR. Distinct Dendritic Cell Subsets Differentially Regulate the Class of Immune Response in Vivo. Proc Natl Acad Sci USA. 1999;96:1036–1041. doi: 10.1073/pnas.96.3.1036. PubMed DOI PMC

Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in Dendritic Cells Stimulated in Vivo by Tumors Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor or Flt3-Ligand. Cancer Res. 2000;60:3239–3246. PubMed

Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3-Ligand Administration Inhibits Liver Metastases: Role of NK Cells. J Immunol. 1998;161:6164–6170. PubMed

Favre-Felix N, Martin M, Maraskovsky E, Fromentin A, Moutet M, Solary E, Martin F, Bonnotte B. Flt3 Ligand Lessens the Growth of Tumors Obtained After Colon Cancer Cell Injection in Rats but Does Not Restore Tumor-Suppressed Dendritic Cell Function. Int J Cancer. 2000;86:827–834. doi: 10.1002/(SICI)1097-0215(20000615)86:6<827::AID-IJC11>3.0.CO;2-R. PubMed DOI

Lyman SD, Brasel K, Rousseau AM, Williams DE. The Flt3 Ligand: a Hematopoietic Stem Cell Factor Whose Activities Are Distinct From Steel Factor. Stem Cells. 1994;12(Suppl 1):99–107. PubMed

Lyman SD, James L, Johnson L, Brasel K, de Vries P, Escobar SS, Downey H, Splett RR, Beckmann MP, McKenna HJ. Cloning of the Human Homologue of the Murine Flt3 Ligand: a Growth Factor for Early Hematopoietic Progenitor Cells. Blood. 1994;83:2795–2801. PubMed

Lyman SD, James L, Escobar S, Downey H, de Vries P, Brasel K, Stocking K, Beckmann MP, Copeland NG, Cleveland LS. Identification of Soluble and Membrane-Bound Isoforms of the Murine Flt3 Ligand Generated by Alternative Splicing of MRNAs. Oncogene. 1995;10:149–157. PubMed

McClanahan T, Culpepper J, Campbell D, Wagner J, Franz-Bacon K, Mattson J, Tsai S, Luh J, Guimaraes MJ, Mattei MG, Rosnet O, Birnbaum D, Hannum CH. Biochemical and Genetic Characterization of Multiple Splice Variants of the Flt3 Ligand. Blood. 1996;88:3371–3382. PubMed

Savvides SN, Boone T, Andrew KP. Flt3 Ligand Structure and Unexpected Commonalities of Helical Bundles and Cystine Knots. Nat Struct Biol. 2000;7:486–491. doi: 10.1038/75896. PubMed DOI

Lu CM, Yu JF, Huang WD, Zhou X, Zhang WY, Xi H, Zhang XG. Increasing Bioactivity of Flt3 Ligand by Fusing Two Identical Soluble Domains. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002;34:697–702. PubMed

Rozwarski DA, Gronenborn AM, Clore GM, Bazan JF, Bohm A, Wlodawer A, Hatada M, Karplus PA. Structural Comparisons Among the Short-Chain Helical Cytokines. Structure. 1994;2:159–173. doi: 10.1016/S0969-2126(00)00018-6. PubMed DOI

Lyman SD, Stocking K, Davison B, Fletcher F, Johnson L, Escobar S. Structural Analysis of Human and Murine Flt3 Ligand Genomic Loci. Oncogene. 1995;11:1165–1172. PubMed

Taddie JA, Traktman P. Genetic Characterization of the Vaccinia Virus DNA Polymerase: Cytosine Arabinoside Resistance Requires a Variable Lesion Conferring Phosphonoacetate Resistance in Conjunction With an Invariant Mutation Localized to the 3'-5' Exonuclease Domain. J Virol. 1993;67:4323–4336. PubMed PMC

Solheim JC, Reber AJ, Ashour AE, Robinson S, Futakuchi M, Kurz SG, Hood K, Fields RR, Shafer LR, Cornell D, Sutjipto S, Zurawski S, LaFace DM, Singh RK, Talmadge JE. Spleen but Not Tumor Infiltration by Dendritic and T Cells Is Increased by Intravenous Adenovirus-Flt3 Ligand Injection. Cancer Gene Ther. 2007;14:364–371. doi: 10.1038/sj.cgt.7701018. PubMed DOI

Rosel JL, Earl PL, Weir JP, Moss B. Conserved TAAATG Sequence at the Transcriptional and Translational Initiation Sites of Vaccinia Virus Late Genes Deduced by Structural and Functional Analysis of the HindIII H Genome Fragment. J Virol. 1986;60:436–449. PubMed PMC

Chakrabarti S, Sisler JR, Moss B. Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression. Biotechniques. 1997;23:1094–1097. PubMed

Zurkova K, Babiarova K, Hainz P, Krystofova J, Kutinova L, Otahal P, Nemeckova S. The Expression of the Soluble Isoform of HFlt3 Ligand by Recombinant Vaccinia Virus Enhances Immunogenicity of the Vector. Oncol Rep. 2009;21:1335–1343. PubMed

Coupar BE, Oke PG, Andrew ME. Insertion Sites for Recombinant Vaccinia Virus Construction: Effects on Expression of a Foreign Protein. J Gen Virol. 2000;81(Pt 2):431–439. 81 Pt 2:431 -92000. PubMed

Flexner C, Hugin A, Moss B. Prevention of Vaccinia Virus Infection in Immunodeficient Mice by Vector-Directed IL-2 Expression. Nature. 1987;330:259–262. doi: 10.1038/330259a0. PubMed DOI

Nemeckova S, Sroller V, Hainz P, Krystofova J, Smahel M, Kutinova L. Experimental Therapy of HPV16 Induced Tumors With IL12 Expressed by Recombinant Vaccinia Virus in Mice. Int J Mol Med. 2003;12:789–796. PubMed

Perera LP, Goldman CK, Waldmann TA. Comparative Assessment of Virulence of Recombinant Vaccinia Viruses Expressing IL-2 and IL-15 in Immunodeficient Mice. Proc Natl Acad Sci USA. 2001;98:5146–5151. doi: 10.1073/pnas.081080298. PubMed DOI PMC

Natuk RJ, Holowczak JA. Vaccinia Virus Proteins on the Plasma Membrane of Infected Cells. III. Infection of Peritoneal Macrophages. Virology. 1985;147:354–372. doi: 10.1016/0042-6822(85)90138-2. PubMed DOI

McLaren C, Cheng H, Spicer DL, Tompkins WA. Lymphocyte and Macrophage Responses After Vaccinia Virus Infections. Infect Immun. 1976;14:1014–1021. PubMed PMC

Drillien R, Spehner D, Bohbot A, Hanau D. Vaccinia Virus-Related Events and Phenotypic Changes After Infection of Dendritic Cells Derived From Human Monocytes. Virology. 2000;268:471–481. doi: 10.1006/viro.2000.0203. PubMed DOI

Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, Relman DA, Huggins JW. Exploring the Potential of Variola Virus Infection of Cynomolgus Macaques As a Model for Human Smallpox. Proc Natl Acad Sci USA. 2004;101:15196–15200. doi: 10.1073/pnas.0405954101. PubMed DOI PMC

McCraith S, Holtzman T, Moss B, Fields S. Genome-Wide Analysis of Vaccinia Virus Protein-Protein Interactions. Proc Natl Acad Sci USA. 2000;97(9):4879–4884. doi: 10.1073/pnas.080078197. PubMed DOI PMC

Morgan C. Vaccinia Virus Reexamined: Development and Release. Virology. 1976;73:43–58. doi: 10.1016/0042-6822(76)90059-3. PubMed DOI

Morrison DK, Moyer RW. Detection of a Subunit of Cellular Pol II Within Highly Purified Preparations of RNA Polymerase Isolated From Rabbit Poxvirus Virions. Cell. 1986;44:587–596. doi: 10.1016/0092-8674(86)90268-0. PubMed DOI

Bereta M, Bereta J, Park J, Medina F, Kwak H, Kaufman HL. Immune Properties of Recombinant Vaccinia Virus Encoding CD154 (CD40L) Are Determined by Expression of Virally Encoded CD40L and the Presence of CD40L Protein in Viral Particles. Cancer Gene Ther. 2004;11:808–818. doi: 10.1038/sj.cgt.7700762. PubMed DOI

Franke CA, Hruby DE. Association of Non-Viral Proteins With Recombinant Vaccinia Virus Virions. Arch Virol. 1987;94:347–351. doi: 10.1007/BF01310729. PubMed DOI

Gomez CE, Esteban M. Recombinant Proteins Produced by Vaccinia Virus Vectors Can Be Incorporated Within the Virion (IMV Form) into Different Compartments. Arch Virol. 2001;146:875–892. doi: 10.1007/s007050170122. PubMed DOI

Husain M, Weisberg AS, Moss B. Sequence-Independent Targeting of Transmembrane Proteins Synthesized Within Vaccinia Virus Factories to Nascent Viral Membranes. J Virol. 2007;81:2646–2655. doi: 10.1128/JVI.02631-06. PubMed DOI PMC

Mercer J, Traktman P. Investigation of Structural and Functional Motifs Within the Vaccinia Virus A14 Phosphoprotein, an Essential Component of the Virion Membrane. J Virol. 2003;77:8857–8871. doi: 10.1128/JVI.77.16.8857-8871.2003. PubMed DOI PMC

Takahashi T, Oie M, Ichihashi Y. N-Terminal Amino Acid Sequences of Vaccinia Virus Structural Proteins. Virology. 1994;202:844–852. doi: 10.1006/viro.1994.1406. PubMed DOI

da Fonseca FG, Wolffe EJ, Weisberg A, Moss B. Characterization of the Vaccinia Virus H3L Envelope Protein: Topology and Posttranslational Membrane Insertion Via the C-Terminal Hydrophobic Tail. J Virol. 2000;74(16):7508–7517. doi: 10.1128/JVI.74.16.7508-7517.2000. 7508-172000. PubMed DOI PMC

da Fonseca FG, Wolffe EJ, Weisberg A, Moss B. Effects of Deletion or Stringent Repression of the H3L Envelope Gene on Vaccinia Virus Replication. J Virol. 2000;74(16):7518–7528. doi: 10.1128/JVI.74.16.7518-7528.2000. 7518-282000. PubMed DOI PMC

Hsiao JC, Chung CS, Chang W. Vaccinia Virus Envelope D8L Protein Binds to Cell Surface Chondroitin Sulfate and Mediates the Adsorption of Intracellular Mature Virions to Cells. J Virol. 1999;73:8750–8761. PubMed PMC

Niles EG, Seto J. Vaccinia Virus Gene D8 Encodes a Virion Transmembrane Protein. J Virol. 1988;62:3772–3778. PubMed PMC

Weir JP, Moss B. Use of a Bacterial Expression Vector to Identify the Gene Encoding a Major Core Protein of Vaccinia Virus. J Virol. 1985;56:534–540. PubMed PMC

Wilcock D, Smith GL. Vaccinia Virions Lacking Core Protein VP8 Are Deficient in Early Transcription. J Virol. 1996;70:934–943. PubMed PMC

Chung CS, Chen CH, Ho MY, Huang CY, Liao CL, Chang W. Vaccinia Virus Proteome: Identification of Proteins in Vaccinia Virus Intracellular Mature Virion Particles. J Virol. 2006;80:2127–2140. doi: 10.1128/JVI.80.5.2127-2140.2006. PubMed DOI PMC

Ott DE, Coren LV, Chertova EN, Gagliardi TD, Schubert U. Ubiquitination of HIV-1 and MuLV Gag. Virology. 2000;278:111–121. doi: 10.1006/viro.2000.0648. PubMed DOI

Mejean C, Pons F, Benyamin Y, Roustan C. Antigenic Probes Locate Binding Sites for the Glycolytic Enzymes Glyceraldehyde-3-Phosphate Dehydrogenase, Aldolase and Phosphofructokinase on the Actin Monomer in Microfilaments. Biochem J. 1989;264:671–677. PubMed PMC

Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 Genes As DNA Vaccine Against E7-Containing Oncogenic Cells. Virology. 2001;281:231–238. doi: 10.1006/viro.2000.0794. PubMed DOI

Mackett M, Smith GL, Moss B. General Method for Production and Selection of Infectious Vaccinia Virus Recombinants Expressing Foreign Genes. J Virol. 1984;49:857–864. PubMed PMC

Patel AH, Gaffney DF, Subak-Sharpe JH, Stow ND. DNA Sequence of the Gene Encoding a Major Secreted Protein of Vaccinia Virus, Strain Lister. J Gen Virol. 1990;71(Pt 9):2013–2021. doi: 10.1099/0022-1317-71-9-2013. PubMed DOI

Kutinova L, Nemeckova S, Ludvikova V, Kunke D, Otavova M, Vonka V. Nektere Problemy Vyvoje Vakcin Zalozenych Na Rekombinantnim Viru Vakcinie. [Problems Associated With the Development of Vaccines Based on Recombinant Vaccinia Virus] Cas Lek Cesk. 1992;131:770–773. PubMed

Nemeckova S, Stranska R, Subrtova J, Kutinova L, Otahal P, Hainz P, Maresova L, Sroller V, Hamsikova E, Vonka V. Immune Response to E7 Protein of Human Papillomavirus Type 16 Anchored on the Cell Surface. Cancer Immunol Immunother. 2002;51:111–119. doi: 10.1007/s00262-001-0261-3. PubMed DOI PMC

Kutinova L, Ludvikova V, Simonova V, Otavova M, Krystofova J, Hainz P, Press M, Kunke D, Vonka V. Search for Optimal Parent for Recombinant Vaccinia Virus Vaccines. Study of Three Vaccinia Virus Vaccinal Strains and Several Virus Lines Derived From Them. Vaccine. 1995;13:487–493. doi: 10.1016/0264-410X(94)00019-J. PubMed DOI

Joklik WK. The Purification Fo Four Strains of Poxvirus. Virology. 1962;18:9–18. doi: 10.1016/0042-6822(62)90172-1. PubMed DOI

Castro AP, Carvalho TM, Moussatche N, Damaso CR. Redistribution of Cyclophilin A to Viral Factories During Vaccinia Virus Infection and Its Incorporation into Mature Particles. J Virol. 2003;77:9052–9068. doi: 10.1128/JVI.77.16.9052-9068.2003. PubMed DOI PMC

Michl J. Metabolism of Cells in Tissue Culture in Vitro. I. The Influence of Serum Protein Fractions on the Growth of Normal and Neoplastic Cells. Exp Cell Res. 1961;23:324–334. doi: 10.1016/0014-4827(61)90042-8. PubMed DOI

DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of Mutation in Human Cells by Using an Epstein-Barr Virus Shuttle System. Mol Cell Biol. 1987;7:379–387. PubMed PMC

Hamsikova E, Zavadova H, Kutinova L, Ludvikova V, Krchnak V, Nemeckova S, Vonka V. Priming Effect of Recombinant Vaccinia Virus Coding for the Middle Hepatitis B Surface Antigen. Arch Virol. 1990;113:283–289. doi: 10.1007/BF01316681. PubMed DOI

Laemmli UK. Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4. Nature. 1970;227:680–685. doi: 10.1038/227680a0. PubMed DOI

Zubay G, Morse DE, Schrenk WJ, Miller JH. Detection and Isolation of the Repressor Protein for the Tryptophan Operon of Escherichia Coli. Proc Natl Acad Sci USA. 1972;69:1100–1103. doi: 10.1073/pnas.69.5.1100. PubMed DOI PMC

Yang WP, Kao SY, Bauer WR. Biosynthesis and Post-Translational Cleavage of Vaccinia Virus Structural Protein VP8. Virology. 1988;167:585–590. PubMed

Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E. The Complete DNA Sequence of Vaccinia Virus. Virology. 1990;179:247–66. doi: 10.1016/0042-6822(90)90294-2. PubMed DOI

Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3